MedeliX
Start asking

vericiguat

Verquvo · ATC code C01DX22

Also known as: Verisiguat

Key facts
Active substance
vericiguat
Drug class
Vasodilator agent
ATC code
C01DX22
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Verquvo 2.5 mg film-coated tablets / Verquvo 5 mg film-coated tablets / Verquvo 10 mg film-coated tablets
Marketing authorisation holder
Bayer AG
Information as of
2026-10-28

Key facts

Vericiguat (Verquvo, film-coated tablets) is a soluble guanylate cyclase (sGC) stimulator. It is used for symptomatic chronic heart failure with reduced ejection fraction.

What it is used for

  • Adults with symptomatic chronic heart failure with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy; given with other heart failure therapies.

Dosing

  • Starting dose 5 mg once daily; double after approximately 2 weeks to the target maintenance dose of 10 mg once daily, as tolerated.
  • With symptomatic hypotension within the past 4 weeks: start at 2.5 mg once daily, doubling about every 2 weeks to 10 mg.
  • Do not start if SBP <100 mmHg; temporarily down-titrate or stop for symptomatic hypotension or SBP less than 90 mmHg.
  • Take with food; not recommended with eGFR <15 mL/min/1.73 m2, dialysis or severe hepatic impairment.

Contraindications

  • Hypersensitivity to the active substance or any of the excipients.
  • Concomitant use of other sGC stimulators such as riociguat.

Important warnings

  • Symptomatic hypotension can occur, particularly with hypovolaemia, severe left ventricular outflow obstruction, autonomic dysfunction, or with antihypertensives or nitrates.
  • Combination with PDE5 inhibitors (e.g. sildenafil) is not recommended.
  • Not studied with eGFR <15 mL/min/1.73 m2, on dialysis or in severe hepatic impairment.
  • Contains lactose.

Side effects

  • Very common: hypotension (16.4%).
  • Common: anaemia, dizziness, headache, nausea, dyspepsia, vomiting, gastro-oesophageal reflux disease.

Interactions

  • Other sGC stimulators (e.g. riociguat) are contraindicated.
  • PDE5 inhibitors such as sildenafil add to blood pressure lowering; not recommended.
  • Ketoconazole and rifampicin had no clinically meaningful effect on exposure.

Pregnancy and breastfeeding

  • As a precaution, should not be used during pregnancy or in women not using contraception.
  • Breast-feeding: a risk to the child cannot be excluded.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

Source: European Medicines Agency (EMA), product information

Turkey

  • VerquvoBAYER TÜRK KİMYA SAN. LTD. ŞTİ. · 9 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 3 more European countries
Iceland
Verquvo
Liechtenstein
Verquvo
Norway
Verquvo

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Verquvo – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/verquvo-epar-product-information_en.pdf
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  3. Wikidata (CC0): ATC C01DX.

Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.